Ligand validation:6E40

BBJ: N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-{[2-(sulfamoylamino)ethyl]amino}-1,2,5-oxadiazole-3-carboximidamide

BBJ is a Ligand Of Interest in 6E40 designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6E40_BBJ_D_502	60%	8%	0.155	0.941	2.53	2.19	5	5	0	0	100%	1
6E40_BBJ_B_502	48%	6%	0.188	0.933	2.82	2.19	5	5	3	0	100%	1
6E40_BBJ_A_502	16%	7%	0.293	0.866	2.69	2.2	4	5	3	0	100%	1
5WN8_BBJ_B_502	11%	19%	0.282	0.799	1.35	2.1	2	4	3	0	100%	1
6IC2_BBJ_A_302	26%	23%	0.239	0.884	1.11	2.04	2	2	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.